GNTANasdaqBiological Products, (No Diagnostic Substances)
Genenta Science S.p.A.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$0.66−0.02 (-2.40%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2022 Ended Jun 30, 2022 | Oct 25, 2022 | After market close | – | – | – |
Press releases
Announcements Genenta Science S.p.A. filed with the SEC
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
signs Definitive Agreements with Sophia High Tech
EX-99.1 to Form 6-K
office: Milan, via Dell’Annunciata 31
EX-99.1 to Form 6-K
Announces Strategic Transformation into a Biotech, Defense, Aerospace, and
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
office: Milano, via Olgettina n. 58
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
office: Milano, via Olgettina n. 58
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
office: Milano, via Olgettina n. 58
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Provides First Half 2022 Business Update and Financial Results
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EX-99.2 to Form 6-K
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
office: Milan, via Olgettina n. 58
EX-99.1 to Form 6-K